128 related articles for article (PubMed ID: 16250048)
1. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity.
Schofield DJ; Bartosch B; Shimizu YK; Allander T; Alter HJ; Emerson SU; Cosset FL; Purcell RH
Hepatology; 2005 Nov; 42(5):1055-62. PubMed ID: 16250048
[TBL] [Abstract][Full Text] [Related]
2. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
Burioni R; Bugli F; Mancini N; Rosa D; Di Campli C; Moroncini G; Manzin A; Abrignani S; Varaldo PE; Clementi M; Fadda G
Virology; 2001 Sep; 288(1):29-35. PubMed ID: 11543655
[TBL] [Abstract][Full Text] [Related]
3. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments.
Burioni R; Plaisant P; Manzin A; Rosa D; Delli Carri V; Bugli F; Solforosi L; Abrignani S; Varaldo PE; Fadda G; Clementi M
Hepatology; 1998 Sep; 28(3):810-4. PubMed ID: 9731577
[TBL] [Abstract][Full Text] [Related]
4. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
[TBL] [Abstract][Full Text] [Related]
5. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties.
Habersetzer F; Fournillier A; Dubuisson J; Rosa D; Abrignani S; Wychowski C; Nakano I; Trépo C; Desgranges C; Inchauspé G
Virology; 1998 Sep; 249(1):32-41. PubMed ID: 9740774
[TBL] [Abstract][Full Text] [Related]
6. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
Meunier JC; Engle RE; Faulk K; Zhao M; Bartosch B; Alter H; Emerson SU; Cosset FL; Purcell RH; Bukh J
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4560-5. PubMed ID: 15767578
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins.
Shaw ML; McLauchlan J; Mills PR; Patel AH; McCruden EA
J Med Virol; 2003 Jul; 70(3):361-72. PubMed ID: 12766998
[TBL] [Abstract][Full Text] [Related]
8. Conformational epitopes detected by cross-reactive antibodies to envelope 2 glycoprotein of the hepatitis C virus.
Nakano I; Fukuda Y; Katano Y; Hayakawa T
J Infect Dis; 1999 Oct; 180(4):1328-33. PubMed ID: 10479166
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
[TBL] [Abstract][Full Text] [Related]
10. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies.
Mancini N; Canducci F; Carletti S; Berardinelli E; Serafini G; Grieco A; Perotti M; Malcangi G; Danieli MG; Varaldo PE; Clementi M; Burioni R
J Biol Regul Homeost Agents; 2003; 17(2):183-7. PubMed ID: 14518720
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81.
Allander T; Drakenberg K; Beyene A; Rosa D; Abrignani S; Houghton M; Widell A; Grillner L; Persson MAA
J Gen Virol; 2000 Oct; 81(Pt 10):2451-2459. PubMed ID: 10993933
[TBL] [Abstract][Full Text] [Related]
13. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
[TBL] [Abstract][Full Text] [Related]
14. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.
Scheel TK; Gottwein JM; Jensen TB; Prentoe JC; Hoegh AM; Alter HJ; Eugen-Olsen J; Bukh J
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):997-1002. PubMed ID: 18195353
[TBL] [Abstract][Full Text] [Related]
15. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
[TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
Hadlock KG; Lanford RE; Perkins S; Rowe J; Yang Q; Levy S; Pileri P; Abrignani S; Foung SK
J Virol; 2000 Nov; 74(22):10407-16. PubMed ID: 11044085
[TBL] [Abstract][Full Text] [Related]
17. Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein.
Diotti RA; Sautto GA; Solforosi L; Mancini N; Clementi M; Burioni R
New Microbiol; 2012 Oct; 35(4):475-9. PubMed ID: 23109015
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of human monoclonal antibodies against hepatitis C virus envelope glycoproteins.
da Silva Cardoso M; Siemoneit K; Sturm D; Krone C; Moradpour D; Kubanek B
J Med Virol; 1998 May; 55(1):28-34. PubMed ID: 9580883
[TBL] [Abstract][Full Text] [Related]
19. A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization.
Sasayama M; Shoji I; Adianti M; Jiang DP; Deng L; Saito T; Watanabe H; Kawata S; Aoki C; Hotta H
J Med Virol; 2012 Feb; 84(2):229-34. PubMed ID: 22170542
[TBL] [Abstract][Full Text] [Related]
20. Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries.
Bugli F; Mancini N; Kang CY; Di Campli C; Grieco A; Manzin A; Gabrielli A; Gasbarrini A; Fadda G; Varaldo PE; Clementi M; Burioni R
J Virol; 2001 Oct; 75(20):9986-90. PubMed ID: 11559832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
